Physician profile
Danielle Rucci
NPI 1417680638
$1,370.18
in general payments reported to CMS, 2019-2025
15 companies · $702 in 2025
The $702 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $212 · 2024: $456 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $374.00 | 2023-2025 | Trelegy Ellipta, Nucala |
| Baxter Healthcare | $157.65 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $119.97 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.93 | 2024-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $100.96 | 2024-2025 | Airsupra, Tezspire |
| Amgen INC. | $84.46 | 2024-2025 | Tezspire |
| Pharming Healthcare, INC. | $81.51 | 2025 | Ruconest |
| Blueprint Medicines Corporation | $75.22 | 2023-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $62.11 | 2025 | Cuvitru |
| Merck Sharp & Dohme LLC | $54.30 | 2025 | Winrevair, Zerbaxa |
| Pfizer INC. | $52.43 | 2023-2024 | |
| Genentech USA, INC. | $29.10 | 2023 | Xolair |
| Csl Behring | $26.17 | 2025 | Haegarda |
| Ionis Pharmaceuticals, INC. | $26.06 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $24.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Rucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.